Trials / Completed
CompletedNCT02557126
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- JW Pharmaceutical · Industry
- Sex
- Male
- Age
- 20 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety, Pharmacokinetics/Pharmacodynamics and Urate Lowering Effect of URC102 in gout patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | URC102 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2015-09-23
- Last updated
- 2017-01-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02557126. Inclusion in this directory is not an endorsement.